Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report

A. Romero; L. Midaglia; M. T. Salcedo; L. Viladomiu; E. Guillén; I. Bajaña; L. Escolà-Vergé; M. Tintoré; X. Montalban; O. Len

doi:10.1016/j.msard.2020.101973

Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report

A. Romero, L. Midaglia, M. T. Salcedo, L. Viladomiu, E. Guillén, I. Bajaña, L. Escolà-Vergé, M. Tintoré, X. Montalban, O. Len^*

^*Autor corresponent d’aquest treball

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

6 Cites (Scopus)

Resum

Background:: Alemtuzumab is a monoclonal antibody targeting CD-52, used for treating relapsing-remitting multiple sclerosis (RRMS). Methods:: We present a case of a 44-year-old male with RRMS who was admitted due to fever and jaundice after starting treatment with alemtuzumab 12 months ago. Results:: He was diagnosed with hemophagocytic syndrome (HS). Liver biopsy revealed images of hemophagocytosis in Kupffer cells of lobular sinusoid. Management consisted of treatment with corticosteroids. Conclusion:: HS is a severe condition marked by an excessive activation of the immune system that leads to a rapid and progressive multi-organ failure, so it is important to consider it in the differential diagnosis of a fever syndrome following the administration of alemtuzumab.

Idioma original	Anglès
Número d’article	101973
Revista	Multiple Sclerosis and Related Disorders
Volum	40
DOIs	https://doi.org/10.1016/j.msard.2020.101973
Estat de la publicació	Publicada - de maig 2020

Accés al document

10.1016/j.msard.2020.101973

Altres arxius i enllaços

Link to publication in Scopus

Com citar-ho

@article{abef698e4da24f3f91942e3eb3792520,

title = "Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report",

abstract = "Background:: Alemtuzumab is a monoclonal antibody targeting CD-52, used for treating relapsing-remitting multiple sclerosis (RRMS). Methods:: We present a case of a 44-year-old male with RRMS who was admitted due to fever and jaundice after starting treatment with alemtuzumab 12 months ago. Results:: He was diagnosed with hemophagocytic syndrome (HS). Liver biopsy revealed images of hemophagocytosis in Kupffer cells of lobular sinusoid. Management consisted of treatment with corticosteroids. Conclusion:: HS is a severe condition marked by an excessive activation of the immune system that leads to a rapid and progressive multi-organ failure, so it is important to consider it in the differential diagnosis of a fever syndrome following the administration of alemtuzumab.",

keywords = "Adverse effects, Alemtuzumab, Autoimmune disease, Corticosteroids, Hemophagocytic syndrome, Multiple sclerosis",

author = "A. Romero and L. Midaglia and Salcedo, \{M. T.\} and L. Viladomiu and E. Guill{\'e}n and I. Baja{\~n}a and L. Escol{\`a}-Verg{\'e} and M. Tintor{\'e} and X. Montalban and O. Len",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier B.V.",

year = "2020",

month = may,

doi = "10.1016/j.msard.2020.101973",

language = "English",

volume = "40",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier",

}

TY - JOUR

T1 - Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis

T2 - A case report

AU - Romero, A.

AU - Midaglia, L.

AU - Salcedo, M. T.

AU - Viladomiu, L.

AU - Guillén, E.

AU - Bajaña, I.

AU - Escolà-Vergé, L.

AU - Tintoré, M.

AU - Montalban, X.

AU - Len, O.

PY - 2020/5

Y1 - 2020/5

N2 - Background:: Alemtuzumab is a monoclonal antibody targeting CD-52, used for treating relapsing-remitting multiple sclerosis (RRMS). Methods:: We present a case of a 44-year-old male with RRMS who was admitted due to fever and jaundice after starting treatment with alemtuzumab 12 months ago. Results:: He was diagnosed with hemophagocytic syndrome (HS). Liver biopsy revealed images of hemophagocytosis in Kupffer cells of lobular sinusoid. Management consisted of treatment with corticosteroids. Conclusion:: HS is a severe condition marked by an excessive activation of the immune system that leads to a rapid and progressive multi-organ failure, so it is important to consider it in the differential diagnosis of a fever syndrome following the administration of alemtuzumab.

AB - Background:: Alemtuzumab is a monoclonal antibody targeting CD-52, used for treating relapsing-remitting multiple sclerosis (RRMS). Methods:: We present a case of a 44-year-old male with RRMS who was admitted due to fever and jaundice after starting treatment with alemtuzumab 12 months ago. Results:: He was diagnosed with hemophagocytic syndrome (HS). Liver biopsy revealed images of hemophagocytosis in Kupffer cells of lobular sinusoid. Management consisted of treatment with corticosteroids. Conclusion:: HS is a severe condition marked by an excessive activation of the immune system that leads to a rapid and progressive multi-organ failure, so it is important to consider it in the differential diagnosis of a fever syndrome following the administration of alemtuzumab.

KW - Adverse effects

KW - Alemtuzumab

KW - Autoimmune disease

KW - Corticosteroids

KW - Hemophagocytic syndrome

KW - Multiple sclerosis

UR - https://www.scopus.com/pages/publications/85078756493

U2 - 10.1016/j.msard.2020.101973

DO - 10.1016/j.msard.2020.101973

M3 - Article

C2 - 32028116

AN - SCOPUS:85078756493

SN - 2211-0348

VL - 40

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

M1 - 101973

ER -

Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report

Resum

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho